Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -99.00% | -.--% | -.--% |
Valuation
Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
Capitalization 1 | 16.02 | 13.85 | 4.038 | 2.955 | 9.149 | 0.004085 |
Enterprise Value (EV) 1 | 38.75 | 43.66 | 44.68 | 53.51 | 65.31 | 58.9 |
P/E ratio | -0.7 x | -0.6 x | 31.2 x | -0.41 x | -0.56 x | -0 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 0.8 x | 0.7 x | 0.15 x | 0.1 x | 0.3 x | 0 x |
EV / Revenue | 1.93 x | 2.21 x | 1.67 x | 1.85 x | 2.18 x | 1.72 x |
EV / EBITDA | -2.55 x | -4.31 x | 7.94 x | 22.3 x | 15.4 x | 9.81 x |
EV / FCF | -4.41 x | -5.4 x | -12.4 x | 145 x | -12.8 x | -55.7 x |
FCF Yield | -22.7% | -18.5% | -8.1% | 0.69% | -7.82% | -1.79% |
Price to Book | 2.16 x | -1.22 x | -0.22 x | -0.11 x | -0.3 x | -0 x |
Nbr of stocks (in thousands) | 16,716 | 18,028 | 18,024 | 18,024 | 19,996 | 29,620 |
Reference price 2 | 0.9584 | 0.7684 | 0.2240 | 0.1639 | 0.4575 | 0.000138 |
Announcement Date | 31/03/17 | 30/04/19 | 30/04/19 | 21/01/21 | 14/07/21 | 21/06/22 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
Net sales 1 | 20.05 | 19.8 | 26.7 | 28.99 | 30 | 34.17 |
EBITDA 1 | -15.18 | -10.12 | 5.628 | 2.399 | 4.229 | 6.002 |
EBIT 1 | -16.28 | -11.13 | 4.005 | 1.363 | 3.778 | 4.178 |
Operating Margin | -81.16% | -56.21% | 15% | 4.7% | 12.59% | 12.23% |
Earnings before Tax (EBT) 1 | -21.68 | -23.12 | 0.337 | -6.949 | -15.05 | -1.419 |
Net income 1 | -21.69 | -23.13 | 0.1296 | -7.182 | -15.06 | -1.42 |
Net margin | -108.16% | -116.83% | 0.49% | -24.77% | -50.2% | -4.16% |
EPS 2 | -1.372 | -1.275 | 0.007190 | -0.3985 | -0.8119 | -0.0490 |
Free Cash Flow 1 | -8.794 | -8.083 | -3.617 | 0.3684 | -5.106 | -1.057 |
FCF margin | -43.85% | -40.83% | -13.55% | 1.27% | -17.02% | -3.09% |
FCF Conversion (EBITDA) | - | - | - | 15.36% | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 31/03/17 | 30/04/19 | 30/04/19 | 21/01/21 | 14/07/21 | 21/06/22 |
Balance Sheet Analysis
Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
Net Debt 1 | 22.7 | 29.8 | 40.6 | 50.6 | 56.2 | 58.9 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | -1.497 x | -2.945 x | 7.221 x | 21.08 x | 13.28 x | 9.812 x |
Free Cash Flow 1 | -8.79 | -8.08 | -3.62 | 0.37 | -5.11 | -1.06 |
ROE (net income / shareholders' equity) | -153% | 1,422% | -0.87% | 32.1% | 51.9% | 4.26% |
ROA (Net income/ Total Assets) | -21.7% | -17.9% | 7.86% | 2.35% | 5.93% | 6.47% |
Assets 1 | 99.99 | 129.3 | 1.649 | -305.6 | -253.9 | -21.93 |
Book Value Per Share 2 | 0.4400 | -0.6300 | -1.030 | -1.460 | -1.510 | -1.170 |
Cash Flow per Share 2 | 0.3900 | 0.1300 | 0.2400 | 0.2500 | 0.1900 | 0.1500 |
Capex 1 | 0.56 | 0.52 | 1.05 | 0.83 | 0.74 | 0.89 |
Capex / Sales | 2.77% | 2.6% | 3.93% | 2.86% | 2.45% | 2.61% |
Announcement Date | 31/03/17 | 30/04/19 | 30/04/19 | 21/01/21 | 14/07/21 | 21/06/22 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-.--% | 29 | |
-14.35% | 77.13B | |
+14.09% | 8.4B | |
-0.70% | 3.22B | |
+14.70% | 1.64B | |
-10.12% | 1.5B | |
-22.60% | 1.3B | |
-4.20% | 1.25B | |
-10.26% | 1.18B | |
+5.06% | 1.1B |
- Stock Market
- Equities
- PARNF Stock
- Financials Parnell Pharmaceuticals Holdings Ltd